Proteolysis Targeting Chimeras Development Service

It is known that Proteolysis-Targeting Chimeras (Proteolysis targeting chimera) molecules are heterobifunctional molecules that hijack the ubiquitin–proteasome system to degrade target proteins. With a deep understanding of the unique challenges associated with prostate diseases, Alfa Cytology provides one-stop Proteolysis targeting chimeras development services for prostate cancer.

Introduction to Proteolysis Targeting Chimeras

In recent years, basic research on Proteolysis targeting chimera drugs targeting androgen receptor, cell proliferation and transcriptional regulation-related proteins for the treatment of prostate cancer has yielded remarkable results.Proteolysis targeting chimeras are heterodimeric functional molecules that inhibit the entire biological function of target proteins by binding to them and inducing subsequent plasmonic degradation. Proteolysis targeting chimeras make up for the fact that transcription factors, nuclear proteins and other scaffolding proteins that are difficult to treat with conventional small molecule inhibitors.

Fig. 1 The mechanism of Proteolysis targeting chimeras based on the UPS and milestones in the development of Proteolysis targeting chimera technology. (Liu, Z., et al. 2022)

Structure of Proteolysis Targeting Chimeras

The Proteolysis targeting chimera molecule consists of three parts: a ligand that binds to the target protein (POI) at one end, a ligand that binds to the E3 ubiquitin ligase at the other end, and a linker that connects these two parts.

Proteolysis Targeting Chimeras Development for Prostate Cancer

Protein hydrolysis against chimeras (Proteolysis targeting chimeras) technology is now a new therapeutic paradigm. Currently, about 20-25% of protein targets are under investigation, with most of the work focusing on their enzymatic functions.

Table 1. Proteolysis targeting chimera degraders in clinical trials for prostate cancer. (Yedla, P., et al. 2023)

Our Services

Proteolysis targeting chimeras technology has tremendous advantages in overcoming drug resistance and targeting non-druggable targets. Currently there are breakthroughs in drug development for various targets in prostate cancer, especially Proteolysis targeting chimeras for AR. At Alfa Cytology, we strive to develop safer, more effective, and more personalized therapies by constantly advancing the research and development of Proteolysis targeting chimeras.

Design and Synthesis of Proteolysis targeting chimera-POI

• Popular POI Ligands
• Different E3 Ligase Ligands
• Comprehensive Linker Library

In Vitro Screening of Proteolysis targeting chimera-POI

• Cell Proliferation Assay
• Western Blot
• Tumor Cell Inhibition Test

In Vivo Evaluation of Proteolysis targeting chimera-POI

• CDX Models
• PDX Models
• Syngeneic Models

Preclinical Research of Proteolysis targeting chimera-POI

• Efficacy Evaluation
• DMPK/ADME
• Safety Assessment

One-stop Solutions for Proteolysis Targeting Chimeras Development

Alfa Cytology provides one-stop Proteolysis targeting chimeras development services tailored specifically for prostate cancer.

Proteolysis targeting chimeras Synthesis and Screening

Purification of Proteolysis targeting chimeras

Drug Discovery for Proteolysis targeting chimeras Screening

Identifies Candidates

If you are looking to develop innovative Proteolysis targeting chimeras for prostate cancer, our expert team provide comprehensive support. By partnering with us, you'll receive personalized consulting services and efficient project advancement. If you are interested in our services, please don't hesitate to contact us for further information and pricing details.